Atara Biotherapeutics Inc... (ATRA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
13.17
0.86 (6.99%)
At close: Jan 15, 2025, 3:59 PM
13.16
-0.08%
After-hours Jan 15, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
Revenue | 8.57M | 63.57M | 20.34M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 8.89M | 14.57M | 11.38M | 9.87M | 8.11M | 3.78M | 956.00K | 383.00K | 48.00K | n/a | n/a | n/a |
Gross Profit | -313.00K | 49.01M | 8.96M | -9.87M | -8.11M | -3.78M | -956.00K | -383.00K | -48.00K | n/a | n/a | n/a |
Operating Income | -276.01M | -280.51M | -340.46M | -309.05M | -295.68M | -237.11M | -121.53M | -81.24M | -58.45M | -28.16M | -8.62M | -3.23M |
Interest Income | 5.43M | 1.99M | 367.00K | 2.45M | 4.72M | 6.37M | 2.03M | 2.20M | 1.22M | 125.00K | 12.00K | n/a |
Pretax Income | -276.11M | -228.29M | -340.10M | -306.61M | -290.96M | -230.74M | -119.50M | -79.04M | -57.23M | -28.03M | -8.60M | -12.28M |
Net Income | -276.13M | -2.28B | -3.40B | -3.07B | -2.91B | -2.31B | -1.19B | -790.49M | -572.21M | -280.06M | -87.73M | -123.30M |
Selling & General & Admin | 49.80M | 71.55M | 78.80M | 64.40M | 79.58M | 69.65M | 40.33M | 24.73M | 16.83M | 12.71M | 3.76M | 2.50M |
Research & Development | 224.78M | 272.53M | 282.00M | 244.65M | 216.10M | 167.46M | 81.21M | 56.51M | 41.62M | 15.45M | 4.86M | 9.78M |
Other Expenses | n/a | -700.00K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.07M | n/a | n/a |
Operating Expenses | 275.69M | 344.09M | 360.80M | 309.05M | 295.68M | 237.11M | 121.53M | 81.24M | 58.45M | 28.16M | 8.62M | 12.28M |
Interest Expense | 5.29M | 1.99M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -1.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 284.58M | 344.09M | 360.80M | 309.05M | 295.68M | 237.11M | 121.53M | 81.24M | 58.45M | 28.16M | 8.62M | 12.28M |
Income Tax | 15.00K | 12.00K | 46.00K | 15.00K | 12.00K | -44.00K | -14.00K | 10.00K | -9.00K | -25.00K | 170.00K | 51.00K |
Shares Outstanding (Basic) | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K | 733.29K |
Shares Outstanding (Diluted) | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K | 733.29K |
EPS (Basic) | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
EPS (Diluted) | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
EBITDA | -266.00M | -213.72M | -331.12M | -296.74M | -282.86M | -233.33M | -120.58M | -80.86M | -58.40M | -28.15M | -8.61M | -4.09M |
Depreciation & Amortization | 4.83M | 14.57M | 11.38M | 9.87M | 8.11M | 3.78M | 956.00K | 383.00K | 48.00K | 6.00K | 4.00K | 3.23M |